Use of the Salmonella spp type III secretion proteins as a protective vaccination
Wendy L. Picking, Lawrence, KS (US); and William D. Picking, Lawrence, KS (US)
Assigned to University of Kansas, Lawrence, KS (US); and The Board of Regents for Oklahoma State University, Stillwater, OK (US)
Filed by The Board of Regents for Oklahoma State University, Stillwater, OK (US); and University of Kansas, Lawrence, KS (US)
Filed on Oct. 7, 2022, as Appl. No. 17/938,851.
Application 17/938,851 is a continuation of application No. 16/752,802, filed on Jan. 27, 2020, granted, now 11,464,843.
Application 16/752,802 is a continuation of application No. 15/950,735, filed on Apr. 11, 2018, granted, now 10,548,962, issued on Feb. 4, 2020.
Application 15/950,735 is a continuation in part of application No. 15/013,454, filed on Feb. 2, 2016, granted, now 9,950,053, issued on Apr. 24, 2018.
Application 15/013,454 is a continuation in part of application No. 14/437,535, abandoned, previously published as PCT/US2013/066105, filed on Oct. 22, 2013.
Claims priority of provisional application 61/716,911, filed on Oct. 22, 2012.
1. A method of protecting against or treating an infection in a subject at risk of, or infected by a Salmonella serovar, comprising administering to the subject a composition comprising Salmonella pathogenicity island 1 (SPI-1) and Salmonella pathogenicity island 2 (SPI-2) extracellular protein; a physiologically acceptable carrier; wherein the SPI-1 extracellular protein comprises SipD or SipB; wherein the SPI-2 extracellular protein comprises SseB; and wherein the composition is administered in an amount so as to elicit an immune response to a Salmonella serovar SPI-1 and/or SPI-2 antigen in the subject.